MIRM: Strong Q2 revenue, pipeline catalysts, and global expansion set the stage for continued growth

Q2 revenue reached $176.2 million, prompting raised full-year guidance. LIVMARLI's growth is driven by PFIC expansion and international rollout, while multiple pivotal data readouts and a PDUFA date for zilurgisertib are upcoming. Cash flow is expected to turn positive next year.Based on Mirum Phar…